280 related articles for article (PubMed ID: 37474083)
21. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
22. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy.
Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X
Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650
[TBL] [Abstract][Full Text] [Related]
23. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
24. Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy.
Su Z; Xiao Z; Wang Y; Huang J; An Y; Wang X; Shuai X
Small; 2020 Feb; 16(7):e1906832. PubMed ID: 31990457
[TBL] [Abstract][Full Text] [Related]
25. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
27. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
28. A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy.
Li M; Zhao D; Yan J; Fu X; Li F; Liu G; Fan Y; Liang Y; Zhang X
ACS Nano; 2024 May; 18(20):12870-12884. PubMed ID: 38727063
[TBL] [Abstract][Full Text] [Related]
29. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy.
Zeng W; Pan J; Fang Z; Jia J; Zhang R; He M; Zhong H; He J; Yang X; Shi Y; Zhong B; Zeng J; Fu B; Huang M; Liu H
Front Immunol; 2022; 13():925217. PubMed ID: 35795680
[TBL] [Abstract][Full Text] [Related]
30. Targeted Ultrasound Nanobubbles Therapy for Prostate Cancer via Immuno-Sonodynamic Effect.
Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
[TBL] [Abstract][Full Text] [Related]
31. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
32. Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment.
Cheng Z; Xue C; Liu M; Cheng Z; Tian G; Li M; Xue R; Yao X; Zhang Y; Luo Z
Acta Biomater; 2023 Oct; 169():289-305. PubMed ID: 37544392
[TBL] [Abstract][Full Text] [Related]
33. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
35. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
36. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
37. PEG-Sheddable Nanodrug Remodels Tumor Microenvironment to Promote Effector T Cell Infiltration and Revise Their Exhaustion for Breast Cancer Immunotherapy.
Huang T; Zhang Q; Yi J; Wang R; Zhang Z; Luo P; Zeng R; Wang Y; Tu M
Small; 2023 Sep; 19(38):e2301749. PubMed ID: 37211704
[TBL] [Abstract][Full Text] [Related]
38. Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer.
Wang YM; Qiu JJ; Qu XY; Peng J; Lu C; Zhang M; Zhang MX; Qi XL; Lv B; Guo JJ; Guo CY; Li GL; Hua KQ
Oncoimmunology; 2022; 11(1):2034257. PubMed ID: 35154907
[TBL] [Abstract][Full Text] [Related]
39. PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer.
Wan H; Xu B; Zhu N; Ren B
Tumori; 2020 Feb; 106(1):55-63. PubMed ID: 31451071
[TBL] [Abstract][Full Text] [Related]
40. CD200
Wang X; Zha H; Wu W; Yuan T; Xie S; Jin Z; Long H; Yang F; Wang Z; Zhang A; Gao J; Jiang Y; Wang L; Hu C; Wan YY; Li QJ; Symonds ALJ; Jia Q; Zhu B
Sci Transl Med; 2023 Jan; 15(679):eabn5029. PubMed ID: 36652534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
